Roy D. Baynes - 11 Mar 2025 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Director
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Roy D. Baynes
Issuer symbol
NRIX
Transactions as of
11 Mar 2025
Net transactions value
$0
Form type
4
Filing time
13 Mar 2025, 16:09:03 UTC
Previous filing
12 Feb 2025
Next filing
29 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Director Stock Option (right to buy) Award $0 +50,000 $0.000000 50,000 11 Mar 2025 Common Stock 50,000 $13.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/36 of the total shares monthly beginning April 11, 2025, until the option is fully vested on March 11, 2028, subject to the Reporting Person's provision of service to the Issuer on each vesting date.